Every 10-Q that VAXART INC (VXRT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VXRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VXRT filings page.
Vaxart, Inc. reported Q2 2026 revenue of $27.2 million, including $24.3 million from HHS BARDA contracts and $2.9 million from its Dynavax/Sanofi collaboration. For the first half of 2026, revenue was $66.4 million, compared with $60.6 million a year earlier.
Research and development expenses declined year over year, and six‑month net loss was $8.3 million versus $30.6 million in 2025, with slightly positive operating cash flow of $0.7 million. Cash, cash equivalents and short‑term investments totaled $64.0 million as of June 30, 2026.
Management states these resources are not sufficient to fund planned operations for 12 months and raises substantial doubt about continuing as a going concern, even though current plans project runway into the second quarter of 2027. BARDA’s Phase 2b COVID‑19 ATI‑RRPV contract was amended, reducing authorized funding from $460.7 million to $344.8 million. Capital access tools include an unused $50 million at‑the‑market program and a $25.0 million equity line with Lincoln Park, under which only $44,000 has been drawn. Previously disclosed securities litigation has been resolved through a 2022 settlement and a 2026 jury verdict in favor of a co‑defendant, with an opt‑out case dismissed.
Vaxart, Inc. reported a profitable quarter for the three months ended March 31, 2026, driven mainly by U.S. government funding and a new collaboration. Total revenue rose to $39.2 million from $20.9 million, powered by $36.4 million from BARDA government contracts and $2.8 million of collaboration revenue from its Dynavax (now Sanofi) license deal.
Operating expenses were $34.1 million, slightly below the prior year, leading to operating income of $5.2 million versus a loss of $14.9 million a year earlier. Net income reached $5.2 million, or $0.02 per diluted share, compared with a net loss of $15.6 million, or $(0.07) per share.
Vaxart ended the quarter with $61.0 million in cash, cash equivalents and short-term investments and expects this to fund planned operations for at least 12 months, with cash runway projected into the second quarter of 2027. The company also put in place a $25.0 million equity line of credit and has an at-the-market program available under a new 2026 shelf registration to support future capital needs.
Vaxart, Inc. reported third‑quarter results highlighting a sharp rise in government contract revenue and a strengthened liquidity outlook. Revenue reached $72.4 million for the quarter, driven by HHS BARDA contracts tied to the ATI‑RRPV program, while operating expenses were $80.2 million, resulting in an operating loss of $7.8 million and a net loss of $8.1 million (basic and diluted loss per share of $0.04).
Cash, cash equivalents and short‑term investments totaled $28.8 million as of September 30, 2025. The balance sheet reflects $42.7 million in accounts receivable and $43.2 million in unbilled receivables from government contracts, alongside $64.8 million in deferred government revenue. Vaxart recognized $71.8 million of cost‑plus‑fixed‑fee revenue in Q3 under the 2024 ATI‑RRPV Contract.
After quarter‑end, Vaxart entered an exclusive license and collaboration with Dynavax, including a $25.0 million upfront fee and a $5.0 million equity purchase at $0.45 per share, providing approximately $30.0 million in total proceeds. Management reports these actions extend cash runway into the second quarter of 2027. Shares outstanding were 240,069,844 as of November 6, 2025.